Cancer risk estimation of glycidol based on rodent carcinogenicity studies, a multiplicative risk model and in vivo dosimetry. (June 2019)

• Record Type: Journal Article
• Authors: Aasa, Jenny; Granath, Fredrik; Törnqvist, Margareta
• Is Part Of: Food and chemical toxicology. Volume 128(2019)
• Page Start: 54
• Page End: 60
• Publication Date: 2019-06
• Subjects: Glycidol -- Cancer risk estimation -- Multiplicative risk model -- Internal dose -- Hb adducts; AUC area under the concentration-time curve -- b.w. body weight -- diHOPrVal N-(2, 3-dihydroxypropyl)valine -- FITC fluorescein isothiocyanate -- FTH fluorescein thiohydantoin -- Hb hemoglobin -- HRMS high-resolution mass spectrometry; Toxicology -- Periodicals; Food poisoning -- Periodicals; Food Poisoning -- Periodicals; Toxicology -- Periodicals; Toxicologie -- Périodiques; Intoxications alimentaires -- Périodiques; Food poisoning; Toxicology; Periodicals; Electronic journals; 615.9
• DOI: 10.1016/j.fct.2019.03.037
• Languages: English
• ISSNs: 0278-6915

Abstract

Abstract: Here we evaluate a multiplicative (relative) risk model for improved cancer risk estimation of genotoxic compounds. According to this model, cancer risk is proportional to the background tumor incidence and to the internal dose of the genotoxic compound. Furthermore, the relative risk coefficient per internal dose is considered to be approximately the same across tumor sites, sex, and species. In the present study, we demonstrate that the relative risk model is valid for cancer risk estimation of glycidol, a common food contaminant. Published tumor data from glycidol carcinogenicity studies in mice and rats were evaluated in combination with internal dose estimates from hemoglobin adduct measurements in blood from mice and rats treated with glycidol in short-term studies. A good agreement between predicted and observed tumor incidence in responding sites was demonstrated in the animals, supporting a relative risk coefficient that is independent of tumor site, sex, and species. There was no significant difference between the risk coefficients for mice (5.1% per mMh) and rats (5.4% per mMh) when considering internal doses of glycidol. Altogether, this mechanism-based risk model gives a reliable risk coefficient, which then was extrapolated to humans considering internal dose, and background cancer incidence. Graphical abstract: Image 1 Highlights: Glycidol animal cancer test data were evaluated with a multiplicative risk model. In vivo dosimetry of glycidol improved the estimation of the cancer risk coefficient. A relative cancer risk coefficient for glycidol common for rat and mouse was derived. The relative risk coefficient was approximately the same for responding tumor sites. The relative risk coefficient was extrapolated to human exposure levels.